So far all we’ve seen Congress and the administration consider are smaller measures that are, at best, good first steps, but don’t go after the real culprits for high drug prices: big pharmaceutical corporations.
Complicated formulas along the pharmaceutical supply chain let drug manufacturers, wholesalers, retailers and pharmacy benefit managers hide behind a thicket of obscure payment arrangements to bilk public health insurance programs, including Medicaid.
Bad actors in the pharmaceutical industry are engaging in unconscionable practices—including annual price spikes on existing drugs and efforts to decrease competition—that hurt patients and public health and bankrupt families.
Most Americans are affected in some way by rising prescription drug and healthcare prices. Whether you’re personally impacted or hear about the effects of rising costs on a family member or friend, you know things aren’t getting better.
Time after time, Americans have watched our nation’s leaders invest in and open our markets to China with little concern for long-term consequences. When it comes to the threat China poses to the U.S. healthcare industry, we cannot afford to be complacent.
I talk A LOT about jobs. I truly believe that a job is the golden key. A job gave me and my family a shot at the American dream. And I want every American to have that same shot, no matter how they grew up.
The roots of many societal problems are intertwined with the current state of our nation’s broken mental health system. This is an issue that crosses geographic, partisan, gender and socio-economic lines—and it impacts millions of Americans.
As policymakers consider legislative solutions to address our broken healthcare system, one core principle must be made abundantly clear: Our solution must match the scale of the crisis we face. Now is not the time for half-measures.
We can lower patient costs without stifling medical innovation or throwing hospitals into turmoil. It’s possible to achieve commonsense solutions that strengthen our nation’s healthcare system while reducing the burden on consumers.
Reining in fentanyl, improving substance-use disorder care coordination, finding nonaddictive alternatives to treat patients in pain, and continuing to investigate root causes of the crisis are the next fronts in this fight.
Sen. Amy Klobuchar says we need safeguards to protect consumers’ sensitive health data collected by innovative technologies such as health mobile apps, wearables and direct-to-consumer genetic testing.